Cargando…
Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression
Liquid chromatography/electrospray ionization-mass spectrometry revealed plasma metabolic profiles for the antidepressant drug escitalopram (ECTP) and associated clinical responses in subjects with major depressive disorder (MDD). Metabolic profiles contribute to variations in responses to drug trea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Mass Spectrometry Society of Japan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338262/ https://www.ncbi.nlm.nih.gov/pubmed/37456152 http://dx.doi.org/10.5702/massspectrometry.A0123 |
_version_ | 1785071593144188928 |
---|---|
author | Bandu, Raju Lee, Hyun Jeong Lee, Hyeong Min Ha, Tae Hyon Lee, Heon-Jeong Kim, Se Joo Ha, Kyooseob Kim, Kwang Pyo |
author_facet | Bandu, Raju Lee, Hyun Jeong Lee, Hyeong Min Ha, Tae Hyon Lee, Heon-Jeong Kim, Se Joo Ha, Kyooseob Kim, Kwang Pyo |
author_sort | Bandu, Raju |
collection | PubMed |
description | Liquid chromatography/electrospray ionization-mass spectrometry revealed plasma metabolic profiles for the antidepressant drug escitalopram (ECTP) and associated clinical responses in subjects with major depressive disorder (MDD). Metabolic profiles contribute to variations in responses to drug treatment of depression. To assess clinical responses and treatment outcomes, we quantified the levels of metabolites, including those of the parent drug, in plasma samples collected at different time points (days 0, 7, 14, and 42) during treatment of seven patients with MDD. Results showed that mean plasma levels of key metabolites and ECTP at day 7 were significantly associated with the clinical response at 42 days after treatment. Statistical analyses, including principal component analysis, of key metabolites and ECTP samples at different time points clearly distinguished the clinical responders from non-responder subjects. Although further validation with a larger cohort is necessary, our results indicate that early improvement and plasma levels of key metabolites and ECTP are predictive of therapeutic treatment outcomes and thus can be used to guide the use of ECTP. |
format | Online Article Text |
id | pubmed-10338262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Mass Spectrometry Society of Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-103382622023-07-14 Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression Bandu, Raju Lee, Hyun Jeong Lee, Hyeong Min Ha, Tae Hyon Lee, Heon-Jeong Kim, Se Joo Ha, Kyooseob Kim, Kwang Pyo Mass Spectrom (Tokyo) Original Article Liquid chromatography/electrospray ionization-mass spectrometry revealed plasma metabolic profiles for the antidepressant drug escitalopram (ECTP) and associated clinical responses in subjects with major depressive disorder (MDD). Metabolic profiles contribute to variations in responses to drug treatment of depression. To assess clinical responses and treatment outcomes, we quantified the levels of metabolites, including those of the parent drug, in plasma samples collected at different time points (days 0, 7, 14, and 42) during treatment of seven patients with MDD. Results showed that mean plasma levels of key metabolites and ECTP at day 7 were significantly associated with the clinical response at 42 days after treatment. Statistical analyses, including principal component analysis, of key metabolites and ECTP samples at different time points clearly distinguished the clinical responders from non-responder subjects. Although further validation with a larger cohort is necessary, our results indicate that early improvement and plasma levels of key metabolites and ECTP are predictive of therapeutic treatment outcomes and thus can be used to guide the use of ECTP. The Mass Spectrometry Society of Japan 2023 2023-07-06 /pmc/articles/PMC10338262/ /pubmed/37456152 http://dx.doi.org/10.5702/massspectrometry.A0123 Text en Copyright @ 2023 Raju Bandu, Hyun Jeong Lee, Hyeong Min Lee, Tae Hyon Ha, Heon-Jeong Lee, Se Joo Kim, Kyooseob Ha, and Kwang Pyo Kim. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of Creative Commons Attribution Non-Commercial 4.0 International License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Article Bandu, Raju Lee, Hyun Jeong Lee, Hyeong Min Ha, Tae Hyon Lee, Heon-Jeong Kim, Se Joo Ha, Kyooseob Kim, Kwang Pyo Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression |
title | Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression |
title_full | Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression |
title_fullStr | Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression |
title_full_unstemmed | Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression |
title_short | Association between Plasma Metabolic Profiles of the Antidepressant Escitalopram and Clinical Response in Subjects with Depression |
title_sort | association between plasma metabolic profiles of the antidepressant escitalopram and clinical response in subjects with depression |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338262/ https://www.ncbi.nlm.nih.gov/pubmed/37456152 http://dx.doi.org/10.5702/massspectrometry.A0123 |
work_keys_str_mv | AT banduraju associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression AT leehyunjeong associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression AT leehyeongmin associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression AT hataehyon associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression AT leeheonjeong associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression AT kimsejoo associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression AT hakyooseob associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression AT kimkwangpyo associationbetweenplasmametabolicprofilesoftheantidepressantescitalopramandclinicalresponseinsubjectswithdepression |